Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07405645 · ClinicalTrials.gov registry record · NA
Stereotactic MRI-guided Focused Ultrasound Mesencephalotomy
A NA study of Cancer Pain and Head Neck Cancer, sponsored by University of Virginia.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 6
- Study locations
NCT07405645: Recruiting NA study of Cancer Pain and Head Neck Cancer, sponsored by University of Virginia.
NCT07405645 is a NA study of Cancer Pain and Head Neck Cancer that is actively recruiting participants, run by University of Virginia. The registered enrollment target is 20 participants, below the 161-participant average among 15 other Cancer Pain trials with a reported enrollment target (88% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07405645, a NA study of Cancer Pain and Head Neck Cancer, is actively recruiting participants, sponsored by University of Virginia.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 6
- Study locations
Study Summary
This phase 1 multi-site study investigates the safety and initial effectiveness of focused ultrasound lesioning of the contralateral mesencephalon for severe, opioid-resistant pain associated with head and neck cancer and brachial cancer.
Primary Outcome
Safety as assessed from adverse event reporting.
Conditions Studied
Interventions
- DEVICE ExAblate Neuro
Study Locations (6)
Texas
- The University of Texas Southwestern Medical Center - Dallas
- Baylor College of Medicine - Houston
Massachusetts
- Brigham and Women's Hospital - Boston
New York
- Weill Cornell Medicine - New York
Oregon
- Oregon Health and Science University - Portland
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-02-15 |
| Est. Completion | 2029-12-31 |
| Phase | NA |
What NCT07405645 shows while recruiting
NCT07405645 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 161-participant average among 15 other Cancer Pain trials with a reported enrollment target (88% lower).
The record links to 3 conditions, with Cancer Pain appearing as the primary indexed condition, and to 1 intervention - of which ExAblate Neuro is the first listed.
NCT07405645 lists 6 locations in 5 states (Texas, Massachusetts, New York).
Frequently Asked Questions
What is clinical trial NCT07405645 about?
NCT07405645 is a clinical study titled "Stereotactic MRI-guided Focused Ultrasound Mesencephalotomy". This phase 1 multi-site study investigates the safety and initial effectiveness of focused ultrasound lesioning of the contralateral mesencephalon for severe, opioid-resistant pain associated with head and neck cancer and brachial cancer.
What is the current status of trial NCT07405645?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2026-02-15. Estimated completion is 2029-12-31.
What conditions does trial NCT07405645 study?
This clinical trial studies the following conditions: Cancer Pain, Head Neck Cancer, Squamous Cell Cancer of Head and Neck (SCCHN).
What interventions are being tested in trial NCT07405645?
The interventions under investigation include: ExAblate Neuro (DEVICE).
Who is sponsoring clinical trial NCT07405645?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07405645 being conducted?
This trial has 6 study locations across Massachusetts, New York, Oregon, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07405645's enrollment target sits among peer trials
20 15th of 15 higher than 1 of 15 other Cancer Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cognitive Behavioral Theory-assisted Virtual Reality for Chronic CANcer Pain (VR-CAN)
RECRUITING · NA
-
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
RECRUITING · NA
-
Auriculo-Nerve Stimulation on Post-Operative Opioid Requirement
RECRUITING · NA
-
Cancer Pain Management Using a Web-based Intervention
RECRUITING · NA
-
Virtual Reality Therapy for Cancer-Treatment Associated Symptoms
RECRUITING · NA
-
Virtual Reality for Cancer Pain Management
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI